US Patent 11312965 Immunostimulatory sequence oligonucleotides and methods of using the same

Is a

Patent

Patent attributes

Patent Applicant

TriSalus Life Sciences

Current Assignee

TriSalus Life Sciences

Patent Jurisdiction

United States Patent and Trademark Office

Patent Number

11312965

Date of Patent

April 26, 2022

Patent Application Number

16224630

Date Filed

December 18, 2018

Patent Citations

‌

US Patent 10494672 Systems and methods for genetic and biological analysis

‌

US Patent 10612091 Systems and methods for genetic and biological analysis

‌

US Patent 10751412 Combination of a PD-1 antagonist and CPG-C type oligonucleotide for treating cancer

‌

US Patent 10695420 DNA-peptide combination vaccine

‌

US Patent 10174323 Compositions and methods for modulating ATP2A2 expression

‌

US Patent 10196643 Immunostimulatory sequence oligonucleotides and methods of using the same

‌

US Patent 10260071 CpG oligonucleotide analogs containing hydrophobic T analogs with enhanced immunostimulatory activity

‌

US Patent 10260095 Systems and methods for genetic and biological analysis

...

Patent Primary Examiner

‌

Nita M. Minnifield

The invention provides immunomodulatory polynucleotides and methods for immunomodulation of individuals using the immunomodulatory polynucleotides.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

US Patent 11312965 Immunostimulatory sequence oligonucleotides and methods of using the same

Contents

Patent attributes

Timeline

Further Resources

References

Find more entities like US Patent 11312965 Immunostimulatory sequence oligonucleotides and methods of using the same